Sector News

Bristol-Myers Squibb says stops some initiatives in China

March 9, 2016
Life sciences

U.S. drugmaker Bristol-Myers Squibb said on Tuesday it had stopped “certain initiatives” in China, when asked by Reuters to comment on industry chatter it was curbing financial incentives for prescribing doctors.

Payments to healthcare professionals in China are under intense scrutiny after GlaxoSmithKline was slapped with a record $490 million fine for bribery in 2014.

Industry sources cited reports on Chinese social media that Bristol-Myers had announced a clampdown on the use of expenses and speaker fees for doctors.

Reuters could not immediately verify the reports but a company spokesman said in an emailed statement: “Bristol-Myers Squibb has voluntarily stopped certain initiatives in China as the company continues to review its activities and build upon its business model in China.”

Last October, Bristol-Myers agreed to pay $14 million to settle U.S. Securities and Exchange claims its joint venture in China made cash payments and provided other benefits to healthcare providers in China in exchange for prescription sales.

By Ben Hirschler; Editing by Martinne Geller

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.